Neoadjuvant therapy in elderly patients receiving FOLFIRINOX or gemcitabine/nab-paclitaxel for borderline resectable or locally advanced pancreatic cancer is feasible and lead to a similar oncological outcome compared to non-aged patients - Results of the RESPECT-Study - Weniger, Maximilian; Moir, John; Damm, Marko; Maggino, Laura; Kordes, Maximilian; Rosendahl, Jonas; Ceyhan, Gueralp O.; Schorn, Stephan; RESPECT\\-Study Grp (ELSEVIER SCI LTD, 2020)
Keywords: Neoadjuvant chemotherapy; Survival; Advanced age